A Lincoln nurse who specialises in looking after patients with blood disorders has been named Nurse of the Year. Alison Dawson-Meadows, who works for United Lincolnshire Teaching Hospitals NHS Trust, ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. It is almost exclusively found ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) achieved its co-primary endpoints ...

According to research presented at the EAHAD 2024 Annual Congress, a new classification system enhances diagnosis and ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be ...

Ministry of Railways plans to build permanent holding areas at stations for better crowd management ...

Gandhinagar: Haemophilia, a rare hereditary blood disorder that prevents proper blood clotting, affects millions globally and as there is no permanent cure for this, timely treatment is crucial to ...

UK MHRA approves Sobi’s efanesoctocog alfa to prevent and treat bleeding in children and adults with severe or moderate haemophilia A: United Kingdom Monday, February 17, 2025, ...

In part one of the FRONTIER3 study, participants with haemophilia A received once-weekly doses of Mim8 administered under the skin for 26 weeks. In part two, participants had the option to ...